Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
No phase specified Diagnostic Closed Over 18 Other END0003
97454, END0003, NCT00373711, NCT00373711

Trial Description

Summary

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Further Study Information

Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.

Eligibility Criteria

Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center

Treated thyroid cancer.

Detectable levels of Tg.

Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.

Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT

Patients older than 18-year-old.

Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.

Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.

Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.
 Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.

Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.

Pregnant women.

Healthy volunteers.

Patients participating in other research studies.

Trial Contact Information

Trial Lead Organizations/Sponsors

Stanford Cancer Center

Andrei Iagaru

Principal Investigator

Iain Ross McDougall

Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00373711
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.